BioAlliance Pharma S.A. complements its portfolio with a European license for Ondansetron Rapidfilm®

BioAlliance has acquired the commercialization rights in Europe to the thin film formulation of ondansetron from APR/Labtec, leader in oral thin film technology named RapidFilmTM. Ondansetron thin film formulation is a new oral formulation for the prevention of chemotherapy-induced nausea and vomiting, prevention of nausea and vomiting associated with radiotherapy, and post-operative nausea and vomiting.

Based on the results of a recently completed bio-equivalency study, BioAlliance will be preparing registration in Europe. The exclusive license to BioAlliance may total up to EUR 6.0 million with EUR 1 million at signature and EUR 1,25 million at approval and sales milestones up to EUR 3,75 million; in addition royalties on net sales of the product will also be paid.

Anti-emetic therapies constitute one of the largest segments of the supportive care market in Europe, with annual sales of over EUR 400 million in 2007 in the 5 major EU markets (IMS Midas 2007). Ondansetron was the prescription leader in the category in 2007, with about 800 000 prescriptions (as extrapolated from IMS Midas Medical Data 2007).

APR/Labtec's proprietary RapidFilmTM technology is a novel, non- mucoadhesive, fast dissolving oral dosage form. It features a thin film based on a water-soluble polymer. The film disintegrates rapidly within seconds in contact with water or saliva, releases the drug in the mouth and promotes gastrointestinal absorption. The RapidFilmTM dosage form was especially designed for high patient compliance. The application is easy. The patient does not have any swallowing difficulty. The fact that no water intake after administration is needed is very well accepted by patients with nausea.

Dominique Costantini, CEO of BioAlliance said, "We are delighted to collaborate with APR/Labtec and expand our pipeline of supportive care products. With two unique, yet complementary delivery systems of ondansetron in our portfolio, ondansetron oral spray from NovaDel and the oral thin film, we are able to offer patients a better opportunity to find a product that meets their individual needs."

Paolo Galfetti, CEO of APR, stated, "BioAlliance is uniquely positioned to market and sell our ondansetron thin film product and we are very excited about the collaboration. Following approval, ondansetron is expected to be the first prescription drugs to come to market utilizing thin film drug delivery technology".

Contact:
Paolo Galfetti (CEO)
APR Applied Pharma Research S.A., www.apr.ch
Via Corti 5, CH - 6828 Balerna, Switzerland
T: +41 91 6957020

BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address resistance issues. The company has launched its first portfolio product (Loramyc®) in France and already received European Marketing Authorizations in UK, Germany, Belgium, Denmark and Luxemburg. The compound has completed the pivotal Phase III clinical development. The company is also developing a new therapeutic entities program focused on the oncology and infectious disease markets.
For more information, visit BioAlliance Pharma's website at www.bioalliance.com .

Labtec GmbH is a privately owned development company, located in Germany. Labtec is focused on the development of drug delivery systems (transdermal delivery systems, buccal/gingival delivery systems, fast dissolving dosage forms) and contract analytics. It has licensing agreements as well as research and development partnerships with several large pharmaceutical companies throughout the world.

Contact:
Dr. Ingo Lehrke (Managing Director)
Labtec GmbH, www.labtec-pharma.com/
Raiffeisenstrasse 4, D-40764 Langenfeld, Germany
T: +49 2173 9735-0